BACKGROUND:Sertraline, a selective serotonin-reuptake inhibitor, has demonstrated substantial mood improvement in patients with post myocardial infarction or with unstable angina. The impact of sertraline on the prognosis and depression of patients with chronic heart failure (HF) and comorbid major depressive disorder (MDD) is unknown. METHOD: This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of sertraline in the treatment of MDD in patients with HF. The study is designed also to examine the effects of treating depression on cardiac events and morbidity/mortality in patients with HF. Approximately 500 men and women who are >or=45 years of age with current MDD and chronic systolic HF, characterized by left ventricular ejection fraction <or=45% and New York Heart Association class >or=II, comprise the study population. Eligible participants are randomized to either sertraline or placebo for a 12-week acute treatment phase. All patients, regardless of acute treatment phase completion, are followed routinely until the last subject completes 6-month follow-up. Quality of life and certain physiologic parameters, as well as pro-inflammatory and HF biomarkers, that may reflect the impact of sertraline in this particular population are measured at baseline and at the end of the acute treatment phase. CONCLUSION: Because of the high prevalence of depression and its significant adverse impact on prognosis of patients with ischemic heart disease (IHD) and HF, the Safety and Efficacy of Sertraline for Depression in Patients with Chronic Heart Failure (SADHART-CHF) trial aims to assess the effects of sertraline on response of depression as well as on the cardiac prognosis of patients with HF.
RCT Entities:
BACKGROUND:Sertraline, a selective serotonin-reuptake inhibitor, has demonstrated substantial mood improvement in patients with post myocardial infarction or with unstable angina. The impact of sertraline on the prognosis and depression of patients with chronic heart failure (HF) and comorbid major depressive disorder (MDD) is unknown. METHOD: This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of sertraline in the treatment of MDD in patients with HF. The study is designed also to examine the effects of treating depression on cardiac events and morbidity/mortality in patients with HF. Approximately 500 men and women who are >or=45 years of age with current MDD and chronic systolic HF, characterized by left ventricular ejection fraction <or=45% and New York Heart Association class >or=II, comprise the study population. Eligible participants are randomized to either sertraline or placebo for a 12-week acute treatment phase. All patients, regardless of acute treatment phase completion, are followed routinely until the last subject completes 6-month follow-up. Quality of life and certain physiologic parameters, as well as pro-inflammatory and HF biomarkers, that may reflect the impact of sertraline in this particular population are measured at baseline and at the end of the acute treatment phase. CONCLUSION: Because of the high prevalence of depression and its significant adverse impact on prognosis of patients with ischemic heart disease (IHD) and HF, the Safety and Efficacy of Sertraline for Depression in Patients with Chronic Heart Failure (SADHART-CHF) trial aims to assess the effects of sertraline on response of depression as well as on the cardiac prognosis of patients with HF.
Authors: D K Ahern; L Gorkin; J L Anderson; C Tierney; A Hallstrom; C Ewart; R J Capone; E Schron; D Kornfeld; J A Herd Journal: Am J Cardiol Date: 1990-07-01 Impact factor: 2.778
Authors: D L Musselman; A Tomer; A K Manatunga; B T Knight; M R Porter; S Kasey; U Marzec; L A Harker; C B Nemeroff Journal: Am J Psychiatry Date: 1996-10 Impact factor: 18.112
Authors: Christopher M O'Connor; Wei Jiang; Maragatha Kuchibhatla; Susan G Silva; Michael S Cuffe; Dwayne D Callwood; Bosh Zakhary; Wendy Gattis Stough; Rebekka M Arias; Sarah K Rivelli; Ranga Krishnan Journal: J Am Coll Cardiol Date: 2010-08-24 Impact factor: 24.094
Authors: Jeff C Huffman; Rachel A Millstein; Carol A Mastromauro; Shannon V Moore; Christopher M Celano; C Andres Bedoya; Laura Suarez; Julia K Boehm; James L Januzzi Journal: J Happiness Stud Date: 2015-10-19
Authors: Julie Adams; Maragatha Kuchibhatla; Eric J Christopher; Jude D Alexander; Greg L Clary; Michael S Cuffe; Robert M Califf; Ranga R Krishnan; Christopher M O'Connor; Wei Jiang Journal: Psychosomatics Date: 2012-01-24 Impact factor: 2.386
Authors: Glen L Xiong; Kevin Prybol; Stephen H Boyle; Russell Hall; Robert D Streilein; David C Steffens; Ranga Krishnan; Joseph G Rogers; Christopher M O'Connor; Wei Jiang Journal: Psychosom Med Date: 2015-09 Impact factor: 4.312
Authors: R R Rubin; S A Gaussoin; M Peyrot; V DiLillo; K Miller; T A Wadden; D S West; R R Wing; W C Knowler Journal: Diabetologia Date: 2010-04-28 Impact factor: 10.122